Dec 30, 2025 • Stock Traders Daily
NEUTRAL
Behavioral Patterns of AXSM and Institutional Flows
This article analyzes Axsome Therapeutics Inc. (NASDAQ: AXSM) focusing on near-term neutral sentiment amidst mid and long-term strength. It highlights resistance testing, an exceptional 37.5:1 risk-reward short setup, and offers three distinct AI-generated trading strategies. The strategies include position trading, momentum breakout, and risk hedging, each tailored for different risk profiles and holding periods, supported by multi-timeframe signal analysis.
Dec 23, 2025 • MarketBeat
SOMEWHAT-BEARISH
Voya Investment Management LLC Decreases Stake in Axsome Therapeutics, Inc. $AXSM
Voya Investment Management LLC reduced its stake in Axsome Therapeutics, Inc. by 18.1% in the third quarter, selling 25,239 shares and holding 114,050 shares valued at approximately $13.85 million. The company reported a significant revenue increase but missed EPS expectations, remaining unprofitable with a negative return on equity. Several analysts maintain a "Moderate Buy" consensus rating with a price target of $179.88, despite recent insider selling activities.
Dec 19, 2025 • The Globe and Mail
BULLISH
Axsome Therapeutics (AXSM) Gets a Buy from Jefferies
Jefferies maintained a Buy rating on Axsome Therapeutics (AXSM) with a price target of $200.00. This follows RBC Capital's Buy rating and contrasts with TR | OpenAI – 4o's Hold rating on the company. Axsome Therapeutics reported a quarterly revenue of $170.99 million and a GAAP net loss of $47.23 million for the quarter ending September 30.
Dec 19, 2025 • Investing.com
BULLISH
Axsome Therapeutics stock hits all-time high at 152.98 USD
Axsome Therapeutics Inc. (AXSM) stock reached an all-time high of $152.98, marking a significant milestone driven by strong investor confidence and impressive growth. The company reported a 67.08% increase over the past year and a 73.74% year-to-date return, showcasing its successful strategies and innovations. Axsome also announced strong Q3 2025 revenues and strategic acquisitions in the epilepsy treatment space, reinforcing its growth trajectory in the biopharmaceutical sector.
Dec 15, 2025 • MarketBeat
NEUTRAL
Castleark Management LLC Buys 19,250 Shares of Axsome Therapeutics, Inc. $AXSM
Castleark Management LLC significantly increased its stake in Axsome Therapeutics, purchasing an additional 19,250 shares in Q2 to bring its total to 38,040 shares valued at approximately $3.97 million. Despite this institutional buying, major insider selling by the CEO and COO has occurred, with insiders cumulatively disposing of 364,798 shares worth $47.53 million recently. Analysts maintain a "Moderate Buy" rating for Axsome with an average price target of $179.88, reflecting optimism despite the company missing EPS estimates and remaining unprofitable in its last earnings report.
Dec 14, 2025 • Simply Wall Street
BULLISH
Will Stronger Results And Bullish Analyst Coverage Change Axsome Therapeutics' (AXSM) Risk‑Reward Narrative?
Axsome Therapeutics has seen renewed positive analyst coverage and improved quarterly results, with higher revenue and a narrower net loss. These developments suggest potential improvements in operational efficiency and sustained confidence in its central nervous system therapy portfolio. Investors are now evaluating how these changes will impact the company's investment narrative and future risk-reward profile, particularly regarding its path to profitability given ongoing heavy spending.